Venture Capital

Newcomer Candid Therapeutics is set to unveil its T-cell engager platform at J.P. Morgan, a move that could shake up the autoimmune treatment landscape.

Early trial data for IKS014 reveals a high clinical benefit rate in pre-treated oesophageal cancer, offering a new beacon of hope for a hard-to-treat disease.

Iron Software funds biochar kilns in Chiang Mai, tackling an environmental crisis that threatens the city's 'mini Silicon Valley' status.

As chip supplier Ultra Clean Holdings presents to investors, the industry watches. Can its outlook signal broader market health and AI-driven expansion?

Nearing its 100th anniversary, global engineering firm Syska Hennessy unveils a new brand and a 10-year plan focused on tech and innovation.

Menlo Ventures promotes General Counsel Deborah Carrillo to Partner, a move reflecting a crucial industry shift where legal expertise is now a core strategic asset.

After a $10M Kickstarter success, LiberNovo's new Omni chair at CES blends biophilic design with bionic tech to challenge the sedentary workday.

With new CEO Libby Morgan, media agency NOVUS pivots from hyperlocal buyer to a full-funnel growth partner, signaling a major industry shift.

Inspira Technologies announces a landmark deal to acquire a liquid biopsy firm, securing a $15M investment at a $180M valuation to enter the cancer market.

IP Atlas Media launches IPAC, a new model for valuing intellectual property, aiming to redefine economic strength in a world driven by intangible assets.

With a fresh funding series, Clipto.AI is pioneering a privacy-first future where powerful AI processes your sensitive content directly on your device.

Family safety app Life360 acquires ad-tech firm Nativo, using its vast location data to build an ad empire. Can it balance profit with user privacy?

As it marks 32 years, Alexandria Real Estate Equities proves its resilience, dominating the market it created amid industry-wide headwinds.

Lucid crushed its 2025 production goals with a huge Q4 surge, but a widening gap between cars built and sold raises serious questions about demand.

At CES 2026, Ubicept's new toolkit promises to let AI see clearly in the dark and at high speed, ushering in a new era for robotics and autonomous cars.

With a $257M war chest and a veteran team, BlossomHill will showcase its innovative pipeline for lung cancer and leukemia at the pivotal JPM conference.

With stunning clinical data for its miv-cel therapy, Kyverna is set to outline a new era for autoimmune treatment at the J.P. Morgan conference.

With a key presentation looming, Star Therapeutics aims to showcase its universal hemostatic therapy, VGA039, for von Willebrand disease.

A tiny implant stimulating the vagus nerve offers new hope for severe RA. A landmark study now validates this bioelectric therapy for patients out of options.

With deep institutional and private sector tech experience, new CEO Andrew Bercich is tasked with guiding the U.S. workforce system through a pivotal era.